Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer

PURPOSE: Zolbetuximab (IMAB362) is engineered to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity. We evaluated ADCC activity and the impact of the immune-modulating drugs zoledronic acid (ZA) and interleukin-2 (IL-2) as co-treatment with zolbetuximab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lordick, Florian, Thuss-Patience, Peter, Bitzer, Michael, Maurus, Daniel, Sahin, Ugur, Türeci, Özlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356865/
https://www.ncbi.nlm.nih.gov/pubmed/36607429
http://dx.doi.org/10.1007/s00432-022-04459-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356865/
https://www.ncbi.nlm.nih.gov/pubmed/36607429
http://dx.doi.org/10.1007/s00432-022-04459-3

Ejemplares similares